A randomized trial of Letrozole in postmenopausal women after five years of Tamoxifen therapy for early-stage Breast Cancer. | [Medical Channel: Journal of Modern Dental and Medical Sciences • 2004]

Author(s):

1. Paul E. Goss: Division of Hematology-Oncology, Princess Margaret Hospital, Toronto, ON, Canada

2. James N. Ingle: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02115

3. Silvana Martino: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02116

4. Nicholas J. Robert: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02117

5. Hyman B. Muss: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02118

6. Martine J. Piccart: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02119

7. Monica Castiglione: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02120

8. Dong Sheng Tu: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02121

9. Lois E. Shepherd: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02122

10. Kathleen I. Pritchard: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02123

11. Robert B. Livingston: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02124

12. Nancy E. Davidson: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02125

13. Larry Norton: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02126

14. Edith A. Perez: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02127

15. Jeffrey S. Abram: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02128

16. Patrick Therasse: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02129

17. Michael J. Palmer: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02130

18. Joseph L. Pater: FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02131

Abstract:

Background: In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy - but not tamoxifen therapy of longer duration prolongs disease free and overall survival. The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy. Methods: We conducted a double-blind, placebo controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy. The primary end point was disease free survival. Results: A total of 5187 women were enrolled (median follow-up, 2.4 years). At the first interim analysis, there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the contralateral breast - 75 in the letrozole group and 132 in the placebo group - with estimated, four-year disease-free survival rates of 93 percent and 87 percent, respectively, in the two groups (P

Page(s): 24-30

DOI: DOI not available

Published: Journal: Medical Channel: Journal of Modern Dental and Medical Sciences, Volume: 10, Issue: 3, Year: 2004

Keywords:

Keywords are not available for this article.

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views